In an interesting (and welcome) development, the last couple of days have seen increased attention from the MSM about the success of research using adult stem cells - a success that is translating into solid investment opportunities. On Tuesday I put this post on the Vital Signs Blog and today I'm suggesting you check out this remarkable CNN story which touts biotech companies like Osiris, Cytori, and Aastrom that are concentrating on adult stem cells."From a Wall Street perspective, adult stem cells are a much better investment," said Stephen Dunn of Dawson James Securities. "These are the guys who are going to be in the news in 2007 and 2008."
President Bush recently vetoed a bill that would loosen federal restrictions on funding for embryonic stem cells, and some analysts fear that as a result the best developments in this area will be made overseas.
But work with adult stem cells isn't being held back by funding restraints and political opposition, analysts say.
"Embryonic stem cell research hasn't kept up pace with adult stem cell research," said Dunn. "Adult stem cell research is advancing so far you might not need embryonic stem cells..."
